Inhalation: A Smart Strategy and Increasing Potential for Drug Delivery

Abstract

Inhaled drug delivery is a critical and evolving strategy in modern medicine, offering distinct advantages over oral, intravenous, and transdermal routes. Inhalation provides rapid onset, high local drug concentrations, reduced systemic side effects, and improved patient compliance. Beyond its established role in treating respiratory diseases like asthma and COPD, recent advances have expanded its applications to systemic therapies, vaccines, and biologics. Innovative devices—including dry powder inhalers, soft mist inhalers, and smart inhalers integrated with digital health technologies—enable precise dosing, adherence monitoring, and personalized therapy. Emerging trends such as inhaled nanoparticles, gene and RNA therapies, and inhaled vaccines are redefining the landscape. Despite progress, challenges remain in formulation stability, device compatibility, inter-patient variability, and environmental concerns. Future research should prioritize green technologies, telehealth integration, patient-specific inhaler matching, and broader therapeutic applications beyond pulmonary diseases.

Routes of Drug Administration

Drug delivery is a critical factor in disease therapy and prevention, directly influencing drug safety and effectiveness. Multiple delivery systems exist, each with distinct characteristics. The choice of route depends on three key factors:

Drug Nature

Chemical properties (sensitivity to stomach acid or digestive enzymes), solubility (fat-soluble vs water-soluble), molecular size and structure, and stability against heat, light, or oxygen.

Drug Action

Sites of action (systemic like blood pressure medication vs local like eye drops), required release rate (rapid onset vs sustained release), and accessibility of target cells or organs (some areas like the blood-brain barrier require special designs).

Patient Compliance

Age and physical condition (infants or elderly may not tolerate injections or large pills), acceptability (some patients prefer oral or inhaled over injections), and convenience (complex dosage forms may reduce adherence).

Table 1: Comparison of Drug Delivery Systems

Delivery	Topical Cream	Transdermal Patch	Oral	Intravenous	Intramuscular	Subcutaneous	Microneedle	Inhalation
Description	A cream to be smeared on the skin	An adhesive patch to be placed on the skin	Uptake of drugs by swallowing or drinking through mouth	An injection into a vein and directly into the bloodstream	An injection deep into the muscle to allow the bloodstream to absorb quickly	An injection given just on the subcutaneous tissues	Micro-size needles aligned on the surface of a small patch	Uptake of drugs by inhaler through mouths or noses
Mechanism	Drugs permeate through skin pores	Drugs permeate stratum corneum barrier and diffuse across the skin	Drugs enter the body through digestive tracts	Drugs placed directly in the vein	Drugs placed directly in the muscle	Drugs placed directly in the dermis	Drugs bypass stratum corneum, placed in epidermis or dermis	Drugs enter through respiratory tracts
Action	Local	Local	Systemic	Systemic	Systemic	Systemic	Systemic	Local or Systemic
Onset	Slow	Slow	Slow	Fast	Fast	Fast	Fast	Fast
Pain	No	No	No	Yes	Yes	Yes	No	No
Bioavailability	Poor	Insufficient	Insufficient	Sufficient	Sufficient	Sufficient	Sufficient	Sufficient
Self-admin	Yes	Yes	Yes	No	Possible	No	Yes	Yes

What does "bioavailability" mean in this table? Bioavailability is the percentage of a drug dose that actually reaches your bloodstream in active form. For example, if you swallow a 100 mg pill but only 30 mg makes it into your blood (the rest is destroyed by stomach acid or the liver), the bioavailability is 30%. Intravenous injection is the gold standard at nearly 100% because the drug goes straight into the blood. Inhalation achieves high bioavailability because the lungs have an enormous surface area (roughly the size of a tennis court) and extremely thin membranes, allowing drugs to pass rapidly into the bloodstream with minimal loss.

Cross-section diagram showing drug delivery routes through skin layers — **Figure 2:** Cross-section diagram showing how different drug delivery methods penetrate skin layers. From left: topical cream, transdermal patch, intravenous injection, intramuscular injection, subcutaneous injection, and microneedle. The diagram illustrates the anatomical layers—stratum corneum (10–40 µm), epidermis (50–150 µm), and dermis (1500–4000 µm)—and each method's penetration depth.

Why Inhalation Drugs Are Important

🎯

Direct Delivery to the Lungs

Inhalation delivers drugs directly to the respiratory tract, achieving high local concentrations with rapid absorption through the vast alveolar surface area.

🩺

Effective for Respiratory Diseases

First-line treatment for asthma and COPD. Bronchodilators and corticosteroids delivered directly where they are needed most.

💊

Lower Dosage Requirements

Targeted delivery means smaller doses can achieve therapeutic levels, reducing the total drug burden on the body.

🛡

Reduced Systemic Side Effects

By targeting the lungs directly, inhalation minimizes whole-body drug exposure and its associated side effects.

✅

Non-Invasive and Convenient

No needles required. Patients can self-administer with portable devices, improving compliance and quality of life.

🌍

Potential for Systemic Delivery

The lungs' large surface area and thin membrane enable absorption of biologics like insulin, vaccines, and gene therapies into the bloodstream.

Why can the lungs absorb drugs so efficiently? The alveolar-capillary membrane is the thin barrier between the air sacs in your lungs (alveoli) and the blood vessels surrounding them. It is only about 0.1 to 0.5 micrometers thick — roughly 100 times thinner than a sheet of paper. Your lungs contain around 300 to 500 million alveoli, giving them a combined surface area of 70 to 100 square meters (about the size of half a tennis court). This massive, ultra-thin surface is what makes the lungs so effective at absorbing inhaled drugs directly into the bloodstream, often within seconds.

Diagram showing inhaler device and upper airway anatomy with oral and nasal inhalation routes — **Figure 1:** Basic mechanism of inhalation drug delivery. The diagram shows an inhaler device (left) and the human upper airway (right), illustrating the two routes of inhalation: through the mouth (oral) and through the nostril (nasal), both reaching the trachea.

Types of Inhalation

Inhalation drug delivery can be divided into two main categories: nasal inhalation (targeting the nasal mucosa and olfactory region, with potential CNS access) and oral inhalation (targeting the lungs and alveoli for respiratory and systemic therapy). Each approach has distinct characteristics, applications, and limitations.

What is first-pass metabolism, and why does it matter? When you swallow a pill, the drug is absorbed through the gut and travels directly to the liver via the portal vein before entering general circulation. The liver can break down (metabolize) a large portion of the drug on this "first pass," sometimes destroying 50-90% of it before it ever reaches its target. This is why some oral drugs require higher doses. Nasal inhalation completely bypasses this process — drugs absorb through the nasal lining directly into the bloodstream. Oral inhalation (through the mouth into the lungs) also largely avoids the liver first-pass effect, which is one reason inhaled drugs can work at much lower doses than their oral pill equivalents.

Table 2: Nasal vs Oral Inhalation Comparison

Aspect	Nasal Inhalation	Oral Inhalation
Entry route	Nostril	Mouth
Primary target site	Nasal mucosa	Lungs (alveoli, bronchi)
Onset of action	Fast, especially for local or CNS effects	Fast, especially for bronchodilators and systemic drugs
Absorption site	Nasal epithelium, olfactory region	Alveolar-capillary membrane
Systemic delivery	Possible (eg, desmopressin, naloxone)	Common for asthma, COPD drugs, insulin, etc.
Local delivery use	Allergic rhinitis, nasal congestion	Asthma, COPD, cystic fibrosis
Bypasses first-pass metabolism	Yes	No
Drug form example	Spray, drop, gel	pMDI, DPI, nebulizer
Device	Nasal spray/delivery pump	Inhalers (MDI, DPI), nebulizer
Volume administered	Small (25-200 µL per nostril)	Variable (depends on formulations and devices)
Patient coordination	Low	Moderate to High (especially with MDI)
Bioavailability variability	Moderate, depends on mucociliary clearance	High, depends on inhalation technique
Irritation potential	Possible (nasal dryness, stinging)	Possible (throat irritation, cough)
CNS drug access	Potential for nose-to-brain delivery	Limited (unless systemically absorbed)
Limitations	Nasal pathology, congestion affects delivery	Requires proper technique; less effective in acute distress
Drug examples	Oxymetazoline, naloxone, desmopressin, COVID-19 vaccine (iNCOVACC®)	Salbutamol, fluticasone, tiotropium, insulin, COVID-19 vaccine (Convidecia Air®)

Devices Used for Inhalation

A Quick Guide to Inhaler Types

pMDI (pressurized Metered-Dose Inhaler): The classic "pump" inhaler. It uses a pressurized canister of propellant to deliver a precise dose of medication as a spray. Requires coordinating a button press with a breath, which many patients find tricky — around 70-80% of patients use them incorrectly without training.

DPI (Dry Powder Inhaler): Contains medication as a fine powder that is released by the patient's own breath. No propellant is needed, making it more environmentally friendly. However, it requires a strong, fast inhalation — which can be difficult for children, the elderly, or patients in respiratory distress.

SMI (Soft Mist Inhaler): Produces a slow-moving, long-lasting mist without propellant. The slower mist means less drug gets stuck in the throat and more reaches the lungs, even with weaker breath. The Respimat device is the best-known example.

Nebulizer: Converts liquid medication into a continuous fine mist that the patient breathes normally through a mask or mouthpiece over several minutes. Ideal for infants, the elderly, or hospitalized patients who cannot coordinate with handheld devices.

Table 3: Inhalation Device Types

Device	Characteristic
Nebulizer	Convert liquid medications into mist, useful for infants, elderly, or those with difficulty
Dry Powder Inhaler (DPI)	Breath-activated devices delivering powdered medication
Pressurized Metered-Dose Inhaler (pMDI)	Pressurized canisters delivering a specific dose per puff
Soft Mist Inhalers (SMI)	Deliver a slow-moving mist to improve lung deposition

Table 4: Green Inhaler Technology

Device	Benefit	Example
Dry Powder Inhaler (DPI)	Breath-actuated, no propellant requirement	Ellipta®
pMDI with Smart Dose Counters	Prevention of under-/over-dosing	Digihaler
Soft Mist Inhalers (SMI)	Lower inspiratory effort	Respimat®

Emerging Trends in Inhalation Drug Delivery

Smart Inhaler Technology

Digital inhalers with sensors for dose tracking and adherence monitoring
Bluetooth-enabled devices that sync with apps for remote patient management
AI integration for predictive maintenance of inhalation therapy in chronic diseases

Inhaled Biologics

Biologic drugs delivered directly to the lungs via inhaler, enabling rapid absorption through the lung's large surface area
Peptides, proteins, and antibodies are being reformulated for pulmonary delivery

Nanoparticles & Liposomal Formulations

Nanocarriers improve drug stability, absorption, and enable sustained release
Targeted delivery to specific lung tissues through engineered nanoparticles

Nanoparticles and Liposomes: Tiny Carriers, Big Impact

Nanoparticles are particles smaller than 1,000 nanometers (about 1/70th the width of a human hair). In drug delivery, they serve as microscopic containers that can protect fragile drugs from degradation, control how quickly the drug is released, and even be engineered to target specific cell types in the lungs.

Liposomes are a specific type of nanoparticle made from the same phospholipid material as human cell membranes. Picture a tiny bubble with a water-filled center — water-soluble drugs go inside the bubble, while fat-soluble drugs embed in the bubble wall. Liposomal formulations of the antifungal drug amphotericin B (Ambisome) are already used clinically.

Lipid nanoparticles (LNPs) — the technology behind the Pfizer and Moderna COVID-19 mRNA vaccines — are denser cousins of liposomes. For inhalation, LNPs can be loaded with mRNA or siRNA, spray-dried into powder, and inhaled to deliver genetic instructions directly to lung cells. This is one of the most active areas of inhaled drug research today.

RNA & Target Therapies

Pulmonary delivery of siRNA, mRNA, and CRISPR-Cas components directly to lung cells
Targeting diseases like cystic fibrosis, lung cancer, pulmonary hypertension, and COVID-19

Gene Therapies Explained: siRNA, mRNA, and CRISPR-Cas

siRNA (small interfering RNA): Short RNA molecules that silence specific genes by blocking their messenger RNA. Think of it as putting a mute button on a specific gene. In lungs, siRNA can be used to silence genes that drive inflammation or tumor growth.

mRNA (messenger RNA): Instructs cells to produce a specific protein temporarily. Rather than permanently changing DNA, mRNA provides a short-lived "recipe" — the cell reads it, makes the protein, then the mRNA naturally breaks down. For cystic fibrosis, inhaled mRNA could instruct lung cells to produce the functional CFTR protein they are missing.

CRISPR-Cas: A precision gene-editing tool often described as "molecular scissors." It can cut DNA at exact locations to correct mutations, delete harmful genes, or insert new sequences. Delivering CRISPR components directly to the lungs via inhalation could permanently fix genetic defects in respiratory diseases — though this technology is still in early-stage research for pulmonary applications.

Inhaled Vaccines

Needle-free, mucosal immunity-inducing formulations that intercept pathogens at the first line of defense
Induction of triple immunity: humoral, cellular, and mucosal
COVID-19 accelerated research into inhaled mRNA and adenovirus-based vaccines

Why "triple immunity" matters for respiratory vaccines: Traditional injected vaccines produce humoral immunity (antibodies in the blood) and cellular immunity (T-cells that kill infected cells). But they do not generate strong mucosal immunity — the defense system at the wet surfaces lining your nose, throat, and lungs. Respiratory pathogens like influenza and SARS-CoV-2 first land on these mucosal surfaces. Inhaled vaccines trigger antibodies (especially secretory IgA) and immune cells right at these entry points, intercepting the pathogen before it can establish infection. This is why inhaled vaccines may prevent not just disease, but also transmission — something injectable vaccines struggle to do.

Personalized Inhalation Therapy

Drugs and inhalers specifically designed to suit individual patient needs
Pharmacogenomics and AI algorithms help customize treatment regimens
Patient-specific inhaler-device matching based on inspiratory flow profile

Personalized Inhalation Therapy: A Cystic Fibrosis Case Study

Personalized inhalation therapy represents the frontier of precision medicine applied to respiratory drug delivery. By tailoring drug selection, inhaler device, and dosing regimen to each patient's genotype and lung function, outcomes can be significantly improved. Cystic fibrosis (CF) serves as a compelling case study for this approach.

What is pharmacogenomics? Pharmacogenomics is the study of how a person's unique genetic makeup affects their response to drugs. For example, in cystic fibrosis (CF), over 2,000 different mutations in the CFTR gene have been identified — and different mutations respond to different drugs. The breakthrough drug Trikafta works well for patients with the most common mutation (F508del, found in ~90% of CF patients), but does nothing for patients with other mutations. Pharmacogenomics helps clinicians match the right drug to the right patient based on their specific genetic variant, rather than using a one-size-fits-all approach.

CF Treatment Pipeline

Three inhaled antibiotics (tobramycin, aztreonam, and colistimethate) have been approved for use in patients with cystic fibrosis. Chronic airway infection is a hallmark of the disease, and individualized selection and rotation of inhaled antibiotics--including off-label use--can yield satisfactory therapeutic outcomes. Additionally, personalized phage therapy offers a promising strategy to address antimicrobial-resistant infections in CF patients.

Successes

Targeted delivery of inhaled antibiotics achieves high local drug concentrations while limiting systemic exposure
Individualized antibiotic selection and rotation yields satisfactory therapeutic outcomes in chronic airway infections
Adherence to simplified once-daily inhalation dosing is significantly higher than multiple daily inhalations

Challenges

Intrinsically or acquired antibiotic-resistant organisms limit effectiveness of conventional inhaled antibiotics
Heterogeneity in airway obstruction and mucus accumulation leads to uneven aerosol deposition
Personalized phage therapy and novel formulations require larger clinical trials to establish long-term efficacy and safety

Challenges and Limitations

Despite the many advantages of inhalation drug delivery, significant challenges remain that must be addressed for the field to reach its full potential:

What is mucociliary clearance? Your airways are lined with a thin layer of sticky mucus and millions of tiny hair-like structures called cilia. The cilia beat rhythmically (about 12-15 times per second), sweeping the mucus — along with trapped dust, bacteria, and inhaled particles — upward toward the throat, where it is swallowed or coughed out. This defense mechanism, called mucociliary clearance, is highly effective at keeping your lungs clean. However, it also removes inhaled drug particles before they can be absorbed. This is one of the key challenges in inhalation drug delivery: designing formulations that deposit in the lungs fast enough to take effect before the body's natural cleaning system sweeps them away.

Aspect	Challenges or Limitations
Patient adaptation	Inhaled drugs may not be suitable for all patients such as elderly and infants
Drug and device compatibility	Not all drugs can be effectively formulated for inhalation. Correct use of inhalers is crucial for efficacy
Stability of formulations	Inhaled drugs must remain stable and effective in aerosol form
Pulmonary clearance mechanism	Mucociliary clearance and alveolar macrophages can remove or degrade inhaled drugs
Tolerance	Repeated usage of inhaled drugs might induce tolerance in some patients
Inter-patient variability	Actual inhaled quantity may be variable (not fixed) in taking inhaled drugs every time
Formulation complexity	Biologics may denature during aerosolization
Side-effect	Some patients may be allergic to inhaled drugs
Environmental impact	Hydrofluoroalkane (HFA) propellants in Metered-Dose Inhalers (MDIs) raise climate concerns
Regulatory & commercialization	Combination product approval (device + formulation) poses unique regulatory challenges. Focus on good inhaler technique training in real-world use

Perspectives and Future Directions

Green Technologies

Developing environmentally friendly propellants and advancing propellant-free DPI technology to reduce the carbon footprint of inhaler use.

Telehealth Integration

Remote monitoring through smart inhaler data analytics, cloud-connected devices, and real-time adherence feedback for patients and clinicians.

Patient-Specific Matching

AI-driven inhaler selection based on individual inspiratory flow profiles, lung capacity, and disease characteristics.

Beyond Pulmonary

Expanding inhalation for systemic delivery of biologics, vaccines, and gene therapies—leveraging the lungs as a gateway to the bloodstream.

Conclusions

Inhalation drug delivery offers unique advantages including rapid onset, high local concentration, reduced systemic side effects, and non-invasive self-administration.
Innovation is rapidly expanding applications beyond traditional respiratory diseases to systemic therapies, vaccines, and gene therapy.
Smart inhalers and digital health technologies are enabling a new era of precision and personalized respiratory medicine.
Remaining challenges—formulation stability, device compatibility, inter-patient variability, and environmental impact—require interdisciplinary research.
As device engineering, digital health, and biopharmaceutical research converge, inhalation therapy is becoming an essential component of precision and patient-centric medicine.

References (96 citations)

Bamgbade OA, Richards RN, Mwaba M, et al. Factors affecting pain perception during administration of local anesthetics. 2015.
Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-1268.
Darji MA, Lalge RM, Marathe SP, et al. Excipient stability in oral solid dosage forms. AAPS PharmSciTech. 2018;19(1):12-20.
Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors. Br J Clin Pharmacol. 2003;56(6):588-599.
Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther Deliv. 2017;8(8):647-661.
Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74.
Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease. Handb Exp Pharmacol. 2018;254:1-25.
Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices. J Control Release. 2015;219:139-148.
Lavorini F, Fontana GA, Usmani OS. New inhaler devices. Expert Opin Drug Deliv. 2014;11(10):1567-1583.
See full reference list in the original paper (96 citations total).